Expression of solute carrier family 37 member 2 (SLC37A2) was increased in ALS patients from all studies (SMD ≥ 0.59) with a meta-SMD estimate of 1.22 (p = 3.8 × 10−19) (Figure 2B and Figure S19). This evidence concerns the gene SLC37A2 and amyotrophic lateral sclerosis.